Drug rash tablet

Topical Use Results of a multisite, randomised double-blind, double-analogue, parallel controlled trial showed that patients n = 66) with TTX treated for 12 weeks with a transdermal preparation of MMl (5% at a dose of 0.2 g/ day, applied 3x daily to skin around thyroid plus a placebo tablet) achieved euthyroidism at the same rate as patients with comparable degree of TTX receiving an equivalent oral dose of MMI (10 mg, 3x daily plus a placebo ointment). The incidence of systemic side effects of drug rash, liver dysfxmction, GI reaction, leucopenia were less in the group receiving MMI topically compared to tiie group administered oral MMI (1.5% vs 12.3%) [54 ]. 

Sulfa drugs Mild rash occurred 2 hours after taking a double-strength trimethoprim-sulfamethoxazole tablet prescribed for a urinary tract infection. 

Acamprosate is administered as 1-2 enteric-coated 333-mg tablets three times per day. It is poorly absorbed, and food reduces its absorption even further. Acamprosate is widely distributed and is eliminated renally. It does not appear to participate in drug-drug interactions. The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea) and rash. It should not be used in patients with severe renal impairment. 

A patient has been receiving abdominal radiotherapy for a period of time for the treatment of colon cancer. She has suffered quite serious nausea as a result of the treatment. You have supplied metoclopramide (in 28 packs of 10 mg tablets) to the patient on a regular basis under PGDs. The patient is now complaining that this drug does not seem to work any more. She has also been experiencing facial muscle spasms and wonders if this could be a side effect of her radiotherapy or the drug. In addition, the patient has developed a painful skin rash over the treatment area. 

---